<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00384293</url>
  </required_header>
  <id_info>
    <org_study_id>0524A-041</org_study_id>
    <secondary_id>2006_506</secondary_id>
    <nct_id>NCT00384293</nct_id>
  </id_info>
  <brief_title>Carotid IMT (Intima Media Thickening) Study (0524A-041)(TERMINATED)</brief_title>
  <acronym>ACHIEVE</acronym>
  <official_title>A Worldwide, Double-Blind, Randomized, Placebo-Controlled Study of MK0524A 2g Coadministered With Intensive LDL-C Lowering Therapy Compared to Intensive LDL-C Lowering Therapy Alone on Carotid Artery Intima Media Thickening (cIMT) in Patients With Heterozygous Familial Hypercholesterolemia (heFH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      This is a 105-week clinical study in patients with heterozygous familial hypercholesterolemia
      on intensive Low Density Lipoprotein-cholesterol (LDL-C) lowering therapy intended to assess
      the affects of MK0524A on carotid intima media thickening using ultrasound compared to
      patients taking placebo. There will be 12 scheduled clinic visits involving review of medical
      history, physical exam, vital signs, laboratory testing, ultrasound imaging, and
      electrocardiograms.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">August 2008</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Carotid Intima Media Thickness</measure>
    <time_frame>after 96 weeks of postrandomization treatment</time_frame>
    <description>change in mean carotid intima media thickness defined as a composite measure of the left and right common, bulb, and internal carotid artery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Lipid Profile</measure>
    <time_frame>after 96 weeks of postrandomization treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">937</enrollment>
  <condition>Hypercholesterolemia, Familial</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MK0524A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: niacin (+) laropiprant (MK0524A)</intervention_name>
    <description>niacin (+) laropiprant (2 g) po qd.</description>
    <arm_group_label>1</arm_group_label>
    <other_name>MK0524A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator: placebo</intervention_name>
    <description>niacin (+) laropiprant (2 g) placebo po qd.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are 18 to 70 years of age with Heterozygous Familial Hypercholesterolemia
             and a LDL-C greater than or equal to 100mg/dL and triglycerides less than or equal to
             400mg/dL at Visit 1 while on a stable dose of intensive LDL-C lowering therapy

        Exclusion Criteria:

          -  A condition which, in the opinion of the investigator, might pose a risk to the
             patient or interfere with participating in the study

          -  Patients with less than 80% drug study compliance

          -  Patients with chronic medical conditions known to influence serum lipids or
             lipoproteins or significantly affect the ultrasound acoustic window

          -  Patients with unstable dose of medications

          -  Pregnant or lactating women, or women intending to become pregnant are excluded

          -  Patient with diabetes mellitus that is poorly controlled, or is taking new or recently
             adjusted antidiabetic pharmacotherapy (with the exception of +/- 10 units of insulin)

          -  Patients with the following conditions: high grade stenosis (greater than 75%) of the
             carotid artery, chronic heart failure, uncontrolled/unstable cardiac arrhythmias,
             unstable hypertension, active or chronic hepatobiliary or hepatic disease, HIV
             positive, episode of gout (within 1 year)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Norway</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2006</study_first_submitted>
  <study_first_submitted_qc>October 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2006</study_first_posted>
  <results_first_submitted>July 23, 2009</results_first_submitted>
  <results_first_submitted_qc>July 23, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 2, 2009</results_first_posted>
  <last_update_submitted>September 28, 2015</last_update_submitted>
  <last_update_submitted_qc>September 28, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There was an MK0524A active run-in period prior to randomization. Per protocol, patients were scheduled to receive MK0524A 1g orally once daily for 4 weeks. The MK0524A dose was then increased to 2g (2x 1g tablets), once daily, for an additional 4 weeks prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MK0524A Active Run-In Period</title>
          <description>Patients who received MK0524A during active run-in (Visit 2). Per protocol, patients were scheduled to receive MK0524A 1g orally once daily for 4 weeks. The MK0524A dose was then increased to 2g (2x 1g tablets), once daily, at Visit 3 for an additional 4 weeks prior to randomization.</description>
        </group>
        <group group_id="P2">
          <title>MK0524A, 2 g (Postrandomization Period)</title>
          <description>Patients who were randomized to MK0524A, 2 g (oral administration) once daily.</description>
        </group>
        <group group_id="P3">
          <title>Placebo (Postrandomization Period)</title>
          <description>Patients who were randomized to placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>MK0524A Active Run-In, Pre-randomization</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="937"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Entered Active run-in, MK0524A 1 g</title>
              <participants_list>
                <participants group_id="P1" count="937">Entered active run-in period and received MK0524A 1 g</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>MK0524A Dose Increased to 2 g</title>
              <participants_list>
                <participants group_id="P1" count="813">MK0524A dose increased to 2 g in active run-in period</participants>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="433"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="504"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="120"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not cIMT eligible at Visit 3</title>
              <participants_list>
                <participants group_id="P1" count="340"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial Termination</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Certified Sonographer Not Available</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Unable to Complete cIMT Scan</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-randomization Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="214"/>
                <participants group_id="P3" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received ≥1 Dose of MK0524A Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="214">Received at least one dose of randomized study drug (All Patients as Treated Population)</participants>
                <participants group_id="P3" count="218"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="214"/>
                <participants group_id="P3" count="219"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Trial Termination</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="180"/>
                <participants group_id="P3" count="204"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Randomized in Error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MK0524A, 2 g (Postrandomization Period)</title>
          <description>Patients who were randomized to MK0524A, 2 g (oral administration) once daily.</description>
        </group>
        <group group_id="B2">
          <title>Placebo (Postrandomization Period)</title>
          <description>Patients who were randomized to placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="214"/>
            <count group_id="B2" value="218"/>
            <count group_id="B3" value="432"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.1" spread="8.94"/>
                    <measurement group_id="B2" value="54.5" spread="8.22"/>
                    <measurement group_id="B3" value="53.8" spread="8.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="138"/>
                    <measurement group_id="B2" value="136"/>
                    <measurement group_id="B3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Carotid Intima Media Thickness</title>
        <description>change in mean carotid intima media thickness defined as a composite measure of the left and right common, bulb, and internal carotid artery.</description>
        <time_frame>after 96 weeks of postrandomization treatment</time_frame>
        <population>study prematurely terminated, no efficacy analyses were performed</population>
        <group_list>
          <group group_id="O1">
            <title>MK0524A Active Run-In Period</title>
            <description>Patients who received MK0524A during active run-in (Visit 2). Per protocol, patients were scheduled to receive MK0524A 1g orally once daily for 4 weeks. The MK0524A dose was then increased to 2g (2x 1g tablets), once daily, at Visit 3 for an additional 4 weeks prior to randomization.</description>
          </group>
          <group group_id="O2">
            <title>MK0524A, 2 g (Postrandomization Period)</title>
            <description>Patients who were randomized to MK0524A, 2 g (oral administration) once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Postrandomization Period)</title>
            <description>Patients who were randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Carotid Intima Media Thickness</title>
          <description>change in mean carotid intima media thickness defined as a composite measure of the left and right common, bulb, and internal carotid artery.</description>
          <population>study prematurely terminated, no efficacy analyses were performed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lipid Profile</title>
        <time_frame>after 96 weeks of postrandomization treatment</time_frame>
        <population>study prematurely terminated, no efficacy analyses were performed</population>
        <group_list>
          <group group_id="O1">
            <title>MK0524A Active Run-In Period</title>
            <description>Patients who received MK0524A during active run-in (Visit 2). Per protocol, patients were scheduled to receive MK0524A 1g orally once daily for 4 weeks. The MK0524A dose was then increased to 2g (2x 1g tablets), once daily, at Visit 3 for an additional 4 weeks prior to randomization.</description>
          </group>
          <group group_id="O2">
            <title>MK0524A, 2 g (Postrandomization Period)</title>
            <description>Patients who were randomized to MK0524A, 2 g (oral administration) once daily.</description>
          </group>
          <group group_id="O3">
            <title>Placebo (Postrandomization Period)</title>
            <description>Patients who were randomized to placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lipid Profile</title>
          <population>study prematurely terminated, no efficacy analyses were performed</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>MK0524A Active Run-In Period</title>
          <description>Patients who received MK0524A during active run-in (Visit 2). Per protocol, patients were scheduled to receive MK0524A 1g orally once daily for 4 weeks. The MK0524A dose was then increased to 2g (2x 1g tablets), once daily, at Visit 3 for an additional 4 weeks prior to randomization.</description>
        </group>
        <group group_id="E2">
          <title>MK0524A, 2 g (Postrandomization Period)</title>
          <description>Patients who were randomized to MK0524A, 2 g (oral administration) once daily.</description>
        </group>
        <group group_id="E3">
          <title>Placebo (Postrandomization Period)</title>
          <description>Patients who were randomized to placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10"/>
                <counts group_id="E2" subjects_affected="5"/>
                <counts group_id="E3" subjects_affected="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Acute pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Toe deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Papillary thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arterial stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="395"/>
                <counts group_id="E2" subjects_affected="74"/>
                <counts group_id="E3" subjects_affected="54"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="52" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Burning Sensation</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="184" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="937"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="214"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="218"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>After a detailed review of pooled carotid IMT data from contemporary studies, the Steering Committee recommended that Merck prematurely stop the study; as designed, the study was significantly underpowered. Efficacy analyses were not performed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

